Postagens
How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non–Small-Cell Lung Cancer
- Gerar link
- X
- Outros aplicativos
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: A network meta-analysis (NMA) of randomized controlled trials (RCTs)
- Gerar link
- X
- Outros aplicativos
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer
- Gerar link
- X
- Outros aplicativos
Biomarker analysis of PALLET: A neoadjuvant trial of letrozole (L) ± palbociclib (P).
- Gerar link
- X
- Outros aplicativos
Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Baseline data from the RIBANNA study.
- Gerar link
- X
- Outros aplicativos
Resistência intrínseca de Abemaciclib apos uso de Palbociclib com uso menor que 120 dias , mas respostas interessantes acima 251 dias
- Gerar link
- X
- Outros aplicativos